BAX 930

Drug Profile

BAX 930

Alternative Names: BAX930; rADAMTS13 - Shire/Kaketsuken; Recombinant ADAMTS13 - Shire/Kaketsuken; SHP 655

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Kaketsuken
  • Developer Shire
  • Class Antihaemorrhagics; Disintegrins; Enzymes; Metalloproteases; Recombinant proteins
  • Mechanism of Action ADAM protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombotic thrombocytopenic purpura

Most Recent Events

  • 21 Feb 2017 Shire plans a phase III trial for Thrombotic thrombocytopenic purpura (Shire pipeline, February 2017)
  • 03 Dec 2016 Safety, pharmacokinetic and pharmacodynamic data from a phase I trial in Thrombotic thrombocytopenic purpura presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top